Peer Review History
| Original SubmissionMay 7, 2021 |
|---|
|
PONE-D-21-15158 How do multi-morbidity and polypharmacy affect general practice attendance and referral rates? A retrospective analysis of consultations. PLOS ONE Dear Dr. O'Regan, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Aug 09 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Vijayaprakash Suppiah, PhD Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (a) whether consent was informed and (b) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information. If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information. 3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. In your revised cover letter, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. We will update your Data Availability statement on your behalf to reflect the information you provide. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Dear Editor, thank you for asking me to review this paper submission. Comments: 1) Abstract: Methods not clearly described. How practices were in the Research Network (72 practices were invited to participate but were there lots more practices who were not included? If so, how were the 72 selected?). If 68 practices selected, each contributing 100 patients, why isnt the sample 6800 patients? Were findings 'adjusted' or 'unadjusted', e.g. for age, gender, deprivation; it would be helpful to know in the Abstract if this is a univariate or multivariate analysis. 2) Introduction: Reference 5 is cited as evidence of 'the recent funding strategy' for primary care. However, it's worth clarifying that much of this funding in England will be allocated to Primary Care Networks (practices working collaboratively within a locality with a population health agenda) rather than being allocated to individual practices in the traditional way. 3) Introduction: Reference 14 is misquoted. The authors state: 'Multi-morbidity, defined as having at least two chronic diseases (13), is present in over one quarter of adults attending general practice...(14)'. In fact, multimorbidity is present in over a quarter of those REGISTERED at general practices, but account for a much higher proportion of those ATTENDING the practice. 4) Introduction: the authors state: 'Therefore, the manual searching of patient records to investigate practice network or national databases is considered to be preferable as they overcome the limitations of coding...'. This provides a strong justification for this study. Studies of coded data are likely to miss cases of multimorbidity (MM). However, the converse should be acknowledged - that a study purely of primary care data will miss emergency presentations to secondary care, which bypass primary care (although these should be recorded retrospectively in primary care case-notes). 5) Methods: as per the Abstract, it's not clear if the Network of GP practices consisted of more than 72 practices. Nor why <100 cases were recruited in each practice 6) Methods: the authors used Cramer’s V to measure strength of association. This is not a commonly used test. How does it differ from Pearson's r value? My reading is that this study has used univariate parametric correlation coefficients, but I may be mistaken. It is important that the readers know how the data was analysed (univariate presumably, parametric or non-parametric associations?) 7) Results: we need a clear definition of MM. Which MM's were included and which were not? Without that list, it's not possible to make sense of the finding: 'The prevalence of multi-morbidity was 38%...' 8) Results, Figure 1. The authors state: 'Fig 1 illustrates that with each 10-year increase in age, the rates of attendance to the GP and practice nurse increase.' But they haven't demonstrated this, at least not without further Stats analysis. What if the mean attendance rate confidence intervals overlapped for each 10-year attendance rate value? Without CI's or a test of difference, the authors cannot conclude that there is a difference in these rates. The same applies to the data shown in Figures 2&3. This is an essential revision required before publication. 9) Discussion: The authors do have a key finding that is of importance: 'However, the ratio of attendance to the GP and referral to hospital remained relatively stable between 6.9 and 9.6. These figures indicate that much of the management of older patients, patients with considerable multimorbidity or polypharmacy are managed in general practice.' This is important and needs emphasis. 10) Discussion, Strengths and Limitations: the authors state: ' This approach of using multiple sources has been considered advantageous rather than relying on adherence to coding by the GPs'. I suspect the authors don't have the all-important data which would provide a strong justification for their approach. Namely, how much of the data they found were buried away in un-coded data? That would justify manual data searching as in this study, and as opposed to electronic data searching of coded (no freetext) anonymised databases such as CPRD. 11) Discussion, Strengths and Limitations: there are many limitations which are not mentioned. A key limitation is how MM was classified (what was and what was not an MM). Why weren't Health Care Assistant consultations included or other healthcare providers within primary care (such as dietitians, midwives, physios etc, if present)? Also, as stated above, what about patients accessing hospital care by bypassing their GP, e.g. emergency admissions - was this data retrospectively captured through inclusion of hospital discharge summaries (this isnt clear in the Methods). only' Reviewer #2: The study objectively shows what many GPs feel on a daily routine: the workload is increasing, the patient cases are becoming more and more complex. Thus, GPs need new tools to be able to treat patients as efficiently and professionally as possible. In my view, the most important result of their study is the constant rate of referrals to hospital. The protective effect for the clinics should not be underestimated. The results of the study are comprehensible and answer the research question. Essentially, I still miss a more detailed description of the data collected: What were the characteristics of the participating GP practices? Number of doctors, age, number of patients, etc. Is there information on the most common diseases or medication groups that led to the definition of multimorbidity and polypharmacy? In which specialist departments were the patients referred? Are there diseases that led to particularly frequent referrals - where did outpatient care in GP practices reach its medical limits? Perhaps additional tables could be used to describe the cohort studied even better and thus make it more comparable for other international data!?. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Mark Ashworth Reviewer #2: Yes: Markus Bleckwenn [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
PONE-D-21-15158R1How do multi-morbidity and polypharmacy affect general practice attendance and referral rates? A retrospective analysis of consultations.PLOS ONE Dear Dr. O'Regan, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Feb 11 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Vijayaprakash Suppiah, PhD Academic Editor PLOS ONE Journal Requirements: Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: (No Response) Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Thank you for asking me to review the revised version of this paper. The revisions have been substantial and greatly improved the standard of this piece of research. I have minor comments only: 1) Abstract: this paper is in large part about hospital referral rates for patients with multimorbidity. More precision is required in the Results section of the Abstract which simply says: 'Half of patients had been referred to hospital in the previous two years'. The exact % figure should be given to one decimal place. 2) Abstract: a key strength of this work is the use of manual record searching rather than searching of an electronic database. This feature should be added to the Abstract e.g. 'manual record searching'. 3) pg22: minor typo. The sentence says 'aged eligibility' and should read 'age eligibility'. Also, pg 28: 'Analysis of a large clinical practice research database in England reported higher health care utilisation in general practice, higher prescription medications...', should read '...higher number of prescription medications', or similar. 4) A further Limitation to be added is that the authors have not identified which LTCs or medications are associated with increased GP/Practice Nurse/Home Visit attendance rates. So we dont know in clinical terms what the drivers are for increased attendance rates (is it mental health conditions, or diabetes, or hypertension, etc etc, all commonly managed in primary care)? Reviewer #2: (No Response) ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: Yes: Markus Bleckwenn [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
How do multi-morbidity and polypharmacy affect general practice attendance and referral rates? A retrospective analysis of consultations. PONE-D-21-15158R2 Dear Dr. O'Regan, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Vijayaprakash Suppiah, PhD Academic Editor PLOS ONE |
| Formally Accepted |
|
PONE-D-21-15158R2 How do multi-morbidity and polypharmacy affect general practice attendance and referral rates? A retrospective analysis of consultations Dear Dr. O'Regan: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Vijayaprakash Suppiah Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .